Talking about women’s health has been a taboo subject for some time, contributing to a lack of innovation in the sector. Still today, many are uncomfortable discussing the topic. Consequently, only 2% of medical products in the pipeline are for women’s health and only 2% of all venture capital dollars go into developing these products. In this episode, we talk with two women in biotech who are trying to change that narrative and infuse more investment in innovations that meet the needs of half the population.
Speakers:
Sabrina Martucci Johnson, CEO
Daré Bioscience
Elizabeth Baily, Managing Director
RH Capital
Listen: [ Ссылка ]
